SCHEMBL3539764

SCHEMBL3539764

Cc1cc(CC(=O)Nc2cccc(-c3nn4ccccc4c3-c3ccnc(Nc4cccc(CN(C)C)c4)n3)c2)on1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK8 P45983 8/20 0.54
MAPK9 P45984 8/20 0.54
SLC2A1 P11166 4/20 0.53
MAPK10 P53779 1/20 0.53
IGF1R P08069 8/20 0.49
EGFR P00533 5/20 0.49
ERBB2 P04626 5/20 0.49
PTK2 Q05397 3/20 0.49
CDK19 Q9BWU1 2/20 0.49
KDR P35968 6/20 0.48
AURKB Q96GD4 4/20 0.48
AURKA O14965 3/20 0.48
RET P07949 4/20 0.47
STK3 Q13188 4/20 0.47
MAP4K5 Q9Y4K4 4/20 0.47
CSF1R P07333 4/20 0.47
MAP4K2 Q12851 3/20 0.47
FLT1 P17948 3/20 0.47
PRKD3 O94806 3/20 0.47
MAP4K4 O95819 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3543542 0.87 IGF1R (0.54) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3543887 0.87 SLC2A1 (0.55) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3543141 0.87 SLC2A1 (0.55) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3539047 0.87 SLC2A1 (0.51) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3542406 0.87 SLC2A1 (0.62) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3543573 0.86 MAPK8 (0.54) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3539400 0.86 IGF1R (0.54) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3541950 0.84 SLC2A1 (0.59) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL3540905 0.82 SLC2A1 (0.65) MAPK8MAPK9SLC2A1MAPK10IGF1R
SCHEMBL13118758 0.81 SLC2A1 (0.62) MAPK8MAPK9SLC2A1MAPK10IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971606-B1 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-04-24 EP disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-7807673-B2 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors GLAXOSMITHKLINE LLC (US) 2010-10-05 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors GLAXOSMITHKLINE LLC 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149456-A1 2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors ERBB2, ERBB3, ERBB4 MAPK8 263/4885MAPK9 203/4885SLC2A1 3810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.